HT
PCVX icon

HAP Trading’s Vaxcyte PCVX Stock Holding History

HAP Trading’s Portfolio PCVX Stock Details PCVX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-25,000
Closed -$78.1K – 822
2024
Q3 		$78.1K Buy
+25,000
New +$2.25M 0.01% 426

Other funds holding PCVX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

HAP Trading's PCVX Position: Q4 2024 in Review

HAP Trading sold out of Vaxcyte (PCVX) in Q4 2024, closing a stake of 10,920 shares — an estimated $1.25M sold.

HAP Trading first reported a position in PCVX in Q3 2024 and held it in 1 quarter. The position peaked at $1.25M in Q3 2024. 323 funds tracked by Wall St. Rank hold PCVX as of Q4 2024.

  • HAP Trading reported no remaining Vaxcyte position as of Q4 2024 after selling out during the quarter.
  • HAP Trading sold 10,920 Vaxcyte shares in Q4 2024, an estimated $1.25M.
  • HAP Trading first reported a position in Vaxcyte in Q3 2024 and held it in 1 quarter.
  • HAP Trading's Vaxcyte position peaked at $1.25M in Q3 2024.
  • 323 funds tracked by Wall St. Rank held Vaxcyte as of Q4 2024.

Based on HAP Trading's 13F filing for Q4 2024, filed 13 Feb 2025.